PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboon

Circulation. 1999 Feb 2;99(4):564-9. doi: 10.1161/01.cir.99.4.564.

Abstract

Background: We have evaluated the use of a mouse/human chimeric anti-platelet-derived growth factor-beta receptor antibody in combination with heparin to inhibit intimal hyperplasia in the saphenous artery of the baboon after balloon angioplasty.

Methods and results: The study evaluated lesion development in sequential injuries made 28 days apart. Each animal received control treatment after the first injury and antibody/heparin therapy after the second injury to the contralateral artery. The antibody was administered by bolus intravenous injections (10 mg/kg) on study days 1, 4, 8, 15, and 22 and heparin coadministered by continuous intravenous infusion at a dose of 0.13 mg/kg per hour. Morphometric analysis of tissue sections showed a 53% decrease in intimal area after antibody/heparin treatment (P=0.005), corresponding to a 40% decrease in the intima-to-media ratio (P=0.005). Smooth muscle cell proliferation in the injured wall, measured at both 4 and 29 days after balloon injury, were similar in the control and antibody/heparin-treated animals.

Conclusions: These data suggest that platelet-derived growth factor plays a key role in the development of intimal lesions at sites of acute vascular injury in the nonhuman primate.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology*
  • Catheterization / adverse effects
  • Cell Division
  • Enzyme-Linked Immunosorbent Assay
  • Heparin / pharmacology*
  • Hyperplasia / etiology
  • Hyperplasia / prevention & control
  • Papio
  • Partial Thromboplastin Time
  • Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors*
  • Receptors, Platelet-Derived Growth Factor / immunology*
  • Time Factors
  • Tunica Intima / drug effects*
  • Tunica Intima / metabolism
  • Tunica Intima / pathology*

Substances

  • Antibodies, Monoclonal
  • Heparin
  • Receptors, Platelet-Derived Growth Factor